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Abstract
Purpose We aimed to study the intracellular expression of 5-
lipoxygenase (5-LOX), the primary competitor with
cyclooxygenase-2 in arachidonic acid metabolism, as inflam-
matory enzymes may be involved in blocking apoptosis and
promoting cancer growth by changing arachidonic acid
metabolism within cells. Our purpose was to investigate the
possible connection between 5-LOX expression and colon
carcinogenesis by characterizing 5-LOX expression in histo-
logically different colonic adenomas, determining the rela-
tionship between high expression of 5-LOX and various
conventional clinicopathological features of adenomas, and
finally characterizingthe histologicallocalizationofcellswith
5-LOX overexpression.
Methods A total of 111 patients were examined and 120
histologically different colonic adenomas analyzed (includ-
ing four cases of intramucosal adenocarcinoma in a polyp).
Immunohistochemical staining with polyclonal anti-5-LOX
antibodies was performed.
Results There was a significant correlation between high 5-
LOX expression and patient age, increased polyp size, high
grade of intraepithelial neoplasia, villous and tubulovillous
adenoma, and histological epithelial localization.
Conclusions We observed a strong positive correlation
between 5-LOX overexpression and the appearance of
typical high-risk factors for malignant transformation in
adenomatous polyps. The results support the role of 5-LOX
in early stages of colon carcinogenesis.
Keywords Colonic adenomas.5-Lipoxygenase.
Immunohistochemistry.Colon carcinogenesis
Introduction
Early diagnosis and efficacious treatment of colorectal
cancer (CRC) are among the greatest challenges for
contemporary gastroenterologists and oncologists. Accord-
ing to current data published by the National Cancer
Institute (Bethesda, MD, USA), CRC is the second most
common malignancy in both males and females, with high
mortality in the USA and Western Europe [1]. It had been
proven that over 90% of all CRCs result from adenomatous
polyps. Multiple clinical, morphological, and genetic
research studies have established the following carcinoge-
netic sequence of events: normal healthy mucosa →
adenoma → adenocarcinoma. Few CRC cases grow de
novo as flat mucosal changes [2].
Not every colonic adenoma involves the same risk of
malignant transformation. It is believed that only about 5%
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DOI 10.1007/s00384-010-0980-zof all patients with detected adenomas will develop cancer.
The commonly recognized risk factors for malignant
transformation of colonic adenomas include a polyp size
of over 10 mm, villous histological type, high degree of
epithelial cell neoplasia, and total number of adenomatous
polyps observed during colonoscopy [1, 2].
Living organisms are protected against the development
of cancer, among other things, through a natural process of
programmed cell death—apoptosis. There is a close
relationship between apoptosis and the intracellular con-
centration of arachidonic acid and its derivatives. An
extremely low concentration of these compounds is not
sufficient to trigger the apoptotic signal cascade, and the
“ageing” cell may be susceptible to neoplastic changes. The
primary groups of eicosanoids are prostaglandins, prosta-
cyclin, thromboxanes, leucotrienes, and lipoxins. Two
enzymatic pathways are necessary for the synthesis of
these compounds: the cyclooxygenase (COX) pathway and
lipoxygenase (LOX) pathway [3].
5-Lipoxygenase is involved in eicosanoid metabolism.
Several isoforms of this enzyme have been previously
described. These are designated according to the arach-
idonic acid derivatives, which are substrates for the specific
metabolic reaction catalyzed by them. These include 5-
LOX, 8-LOX, 12-LOX, 15-LOX-1, and 15-LOX-2 [4, 5]. It
has been shown that both the 5-LOX and 12-LOX
pathways play a significant role in promoting tumor growth
[6–9].
In our study, we have focused on the 5-LOX enzyme—
the most metabolically active LOX isoform. 5-
Lipoxygenase overexpression has been demonstrated in
several human cancers [10–15]. Soumaoro et al. found that
5-LOX expression in human colorectal cancer correlated
with tumor size, depth, and vessel invasion [16]. Little is
known about the role of 5-LOX and other enzymes of
this group in oncogenesis; thus, there is a need to
continue and extend research into the origins of malig-
nant changes in the large bowel. The aim of our study is
to determine the expression of 5-LOX in colonic
adenomas of different histological structures and to
examine the relationship between the expression of this
enzyme and conventional clinicopathological factors of
adenomas. We also aim to establish the tissue layer of
the adenoma in which the high expression of 5-LOX was
most frequently seen.
Materials and methods
Tissue material
In total, 120 colonic adenomas were examined after
removal from 111 patients. Fifty-two (43.3%) adenomas
w e r ee x t r a c t e df r o m4 8w o m e n( a g e d3 6 –81 years,
median =64.5, SD=±11.2), and 68 (56.7%) adenomas were
e x t r a c t e df r o m6 3m e n( a g e d4 2 –85 years; median =63.0,
SD=±10.7). Polypectomy procedures were carried out in
the Gastroenterology Department of Pomeranian Medical
University in Szczecin, Poland. This study did not
include hyperplastic polyps or serrated adenomas (due
to their differing pathogenic origins). Polyps obtained
from patients with an inflammatory bowel disease and
polyposis syndrome were excluded. All collected adeno-
mas were fixed immediately with a 10% solution of
f o r m a l i na n de m b e d d e di np a r a f f i ni nt h eP a t h o l o g y
Department of Medical Faculty, Pomeranian Medical Univer-
sity in Szczecin, Poland. Primary adenoma sections were cut
from paraffin blocks for microscopic slides and stained with
hematoxylin and eosin and then were examined and classified
into different groups by a pathologist, according to the
features listed in Tables 1 and 2.
Immunohistochemistry
Microscopic sections were cut from formalin-fixed
adenoma tissues embedded in paraffin. Sections were
deparaffinized at 68°C overnight, washed with xylene at
the same temperature, and then dehydrated in alcohol.
Cell antigens were recovered by boiling thrice for 7 min
in citrate buffer (pH 6.0). Slides were washed in
phosphate-buffered saline (PBS) solution (pH 7.4),
endogenous peroxidase was blocked with a peroxidase
blocking reagent (DAKOCytomation S2001), and then
slides were washed again in PBS solution (pH 7.4).
Next, tissues were exposedt oad i l u e n t( A n t i b o d y
Diluent DAKOCytomation S0809) and incubated at
room temperature in a primary rabbit polyclonal
antibody anti-5-LOX (Cayman Chemical 160402) solu-
tion. All slides were washed in PBS solution (pH 7.4)
for the third time and incubated with the secondary
antibody (LAB + Kit, HRP DAKOCytomation K0690).
After washing with PBS solution (pH 7.4), immuno-
reaction was visualized by using chromogene (AEC+
High Sensitivity Substrate Chromogene DAKOCytoma-
tion K3469). All slides were then washed with double-
distilled water. Tissues were then stained with Meyer’s
hematoxylin and covered with a mounting medium
(Faramount Aqueous Mounting Medium DAKOCytoma-
tion S3025).
Microscopic evaluation
An assessment of all tissue samples was performed using
the OLYMPUS BX41 light microscope. Every microscopic
image, in exactly the same field of view for all slides, was
examined simultaneously by two of the authors (MPW and
1080 Int J Colorectal Dis (2010) 25:1079–1085BK) using two independent vision tracks. Both the
percentage of 5-LOX-positive cells (quantity score) and
the intensity of chromogene staining of these cells
(intensity score) were assessed in all tissues. In addition,
the location of stained cells was evaluated in terms of their
comparative presence in the epithelium or tissue stroma.
The scoring system proposed by Soslow with our own
modification was used for the classification of tissue images
in terms of examined enzyme expression [17]. The field of
view under a microscope is divided into four parts with all
points from each quadrant noted and analyzed individually.
The final points from both assessing doctors are then
averaged to promote more highly objective results, which
was the aim of our modification of the system. Typical
microscopic images of high 5-LOX expression are shown
in Figs. 1 and 2. Each of the polyps was scored for each
quadrant as follows: staining intensity from the most
intense-colored slide’s field of view, enlarged to ×400,
was compared to the control slide using a scale of 0–3
points (“0”—negative, “1”—weak, “2”—moderate, “3”—
strong) and the percentage of 5-LOX-positive cells was
measured on a scale of 0–4 points (“0”=<1%, “1”=1–25%,
“2”=26–50%, “3”=51–75%, “4”=76–100%). The total
score from the eight fields of view obtained from both
examiners for each of the two categories mentioned above
were then averaged to obtain individual end-values. It
should be noted that the results generated by the two
investigators did not differ significantly; according to
current literature, the values obtained in this scoring system
by the individual evaluators do not vary significantly from the
results obtained by means of a computerized image analyzer
[18]. In the present scoring system, the intensity of staining
points (0–3) and percentage of 5-LOX-positive cell points
(0–4) for all of the slides were multiplied with each other,
resulting in final scores ranging from 0 to 12. These values
correspond to the expression of the examined enzyme in the
tissue; thus, a result of 0–4 points means a total lack or low
expression of the enzyme (negative or questionable result =
normal/no overexpression) and a result of 5 or greater is
considered to be unambiguously positive for overexpression
of the enzyme. Finally, the layer of tissue in which 5-LOX
expression was the highest was determined: (a) epithelium,
(b) tissue stroma, and (c) a similar expression in these two
layers (balanced expression).
Statistics
All relations (p values) between 5-LOX expression and
characteristic features of examined adenomas were calcu-
lated using Fisher’s exact method. In addition, the
relationship between the adenomas’ size and 5-LOX
expression was examined using the U Mann–Whitney
nonparametric method; p<0.05 was considered statistical-
ly significant.
Results
Eighty-one (67.5%) out of the 120 examined adenomas
showed overexpression of 5-LOX. Thirty-nine (32.5%)
adenomas showed either weak or no expression of 5-
LOX. There were significant statistical differences between
5-LOX expression and the following parameters: patient
age, those who had undergone endoscopic polypectomy,
histological type of examined adenomas, grade of intra-
epithelial neoplasia in adenomas’ epithelium, size of
adenomas, adenomas’ location in the large bowel, and
tissue layer inside the adenoma.
Table 1 Clinicopathological variables of examined adenomas
Clinicopathological variables n (%)
Age of patients
a, years
<60 48 (40%)
≥60 72 (60%)
Adenoma type 116 (97%)
Tubular 55 (46%)
Tubulovillous 49 (41%)
Villous 12 (10%)
Adenocarcinoma (intraepithelial) 4 (3%)
Size (mm)
<10 60 (50%)
≥10 60 (50%)
Grade of intraepithelial neoplasia
b
Low 49 (42%)
Moderate 33 (28%)
High 34 (30%)
Adenoma location
Proximal
c 34 (28%)
Cecum 6 (5%)
Ascending colon 15 (12.5%)
Transverse colon 13 (11%)
Distal 86 (72%)
Descending colon 11 (9%)
Sigmoid colon 39 (32.5%)
Rectum 36 (30%)
Number of adenomas during
colonoscopy (in 111 patients)
1 49 (44%)
2–5 50 (45%)
6–10 5 (4.5%)
>10 7 (6.5%)
aTotal of 120 adenomas from 111 patients
bWithout four intraepithelial adenocarcinomas
cWith regard to splenic flexure
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5-Lipoxygenase overexpression was observed in 55
(76.4%) adenomas taken from patients 60 years or older
and in 26 (54.2%) adenomas taken from patients under
60 years of age; this difference was statistically significant
(p<0.0002).
Histological type of adenomas
Seventy-eight (67.2%) adenomas and three (75%) early
adenocarcinomas in the polyps showed a high expression of
5-LOX. High enzyme expression was seen in 12 (100%)
villous adenomas, 39 (79.6%) tubulovillous adenomas, and
27 (49.1%) tubular adenomas. Statistically significant
differences of 5-LOX overexpression were observed be-
tween villous adenomas as compared to tubular adenomas
(p<0.001) and between tubulovillous adenomas as com-
pared to tubular adenomas (p=0.001). There was no
significant difference between villous and tubulovillous
adenomas.
Grade of adenomas’ intraepithelial neoplasia
5-Lipoxygenase overexpression was seen in 28 (82.4%)
adenomas with high-grade intraepithelial neoplasia and in
50 (61%) adenomas with a low or moderate grade of
intraepithelial neoplasia in the epithelium. A statistically
significant difference was observed between different
grades of intraepithelial neoplasia—5-LOX overexpression
was found to be more common in the epithelium of polyps
with a high-grade neoplastic change compared to those with
lesser intraepithelial neoplasia (p=0.026). Four cases of
early adenocarcinoma in polyps were analyzed together
with the group of high-grade intraepithelial neoplasia
adenomas due to the very small number of early adeno-
carcinomas. All other relationships were of no statistical
significance.
Clinicopathological variables n (patients) 5-LOX expression p value
Normal Overexpression
Age of patients, years
<60 48 22 26 0.01
≥60 72 17 55
Gender
Females 48 13 35 NS
Males 63 19 44
Size (mm)
<10 60 33 27 <0.05
≥10 60 6 54
Grade of intraepithelial neoplasia
Low 49 17 32 0.02
Moderate 33 15 18
High 34 6 28
Adenoma location
Proximal 34 14 20 NS
Distal 86 25 61
Number of adenomas during colonoscopy
14 9 1 4 3 5 N S
2–55 0 1 5 3 5
6–10 5 1 4
>10 7 2 5
Tissue layer with an advantage of 5-LOX
overexpressed cells
E
a 84 20 64 <0.002
B
b 25 11 14
TS
c 11 8 3
Adenoma type
Tubular 55 28 27 0.001
Tubulovillous 49 10 39
Villous 12 0 12
Table 2 Clinicopathological
variables and 5-LOX expres-
sion of examined polyps
aEpithelium
bBalance between epithelium and
tissue stroma
cTissue stroma
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5-Lipoxygenase overexpression was observed in 54 (90%)
adenomas with a size of 10 mm or greater and in 27 (45%)
adenomas of a size less than 10 mm; the difference in 5-
LOX expression between the groups was statistically
significant (p<0.000001). This relationship of 5-LOX
overexpression and the size of the adenoma were addition-
ally analyzed with the U Mann–Whitney test, confirming
the strong statistical difference (p<0.000001).
Adenomas’ location in the large bowel
5-Lipoxygenase overexpression was observed in four
(66.7%) adenomas removed from the cecum, in ten
(66.7%) adenomas from the ascending colon, in six
(46.2%) adenomas from the transverse colon, in nine
(81.8%) adenomas from the descending colon, in 32
(82.1%) adenomas from the sigmoid colon, and in 20
(55.6%) adenomas from the rectum. Statistically, significant
differences of 5-LOX overexpression were seen in the
group of transverse colon polyps as compared to those
taken from the sigmoid colon (p=0.01). There was also a
significantly more frequent appearance of 5-LOX over-
expression among adenomas from the sigmoid colon when
compared to the group from the rectum (p=0.01). Other
relationships were not significant.
Tissue layer location of 5-lipoxygenase overexpressed cells
in adenomas
In the group in which all 81 examined adenomas had
high 5-LOX expression, 64 (79%) had the 5-LOX
overexpressed cells located only in the epithelium; in
14 (17.3%) adenomas, we observed 5-LOX-positive cells
exhibiting a balanced location—both in the epithelium
and in the tissue stroma. In three (7.4%) adenomas, the
overexpressed cells were mainly located in the tissue
stroma. Each of these differences was statistically
significant (for all relations; p<0.002).
We did not find any significant differences in 5-LOX
overexpression related to the gender of the patient or to the
total amount of adenomas removed during endoscopic
polypectomy. Table 2 shows all primary results.
Discussion
The exact role played by 5-LOX, the main metabolic
competitor for COX-2, in the mechanism of colonic polyp
formation and transformation to CRC is unknown. Soumaoro
et al. found a relationship between 5-LOX overexpression in
colon cancerand poorprognosis [16]. Recently, it was shown
that 5-LOX is overexpressed in human tubular adenomas of
the colon and cancer specimens, whereas it is only seen in
scattered cells of normal colonic mucosa [19].
This study, which includes 120 colonic adenomas,
comprises one of the largest 5-LOX expression analyses
to date. High expression of 5-LOX was shown in 67.5% of
cases. In this study, 5-LOX overexpression was associated
with histological structure type, degree of intraepithelial
neoplasia in epithelial cells, size and location of adenomas
in the large bowel, and patient age at endoscopic poly-
pectomy. As we have demonstrated in our previous studies,
Fig. 2 Cells with overexpression of 5-LOX (marked with red
chromogene) in early intramucosal adenocarcinomas inside the
polyp—positive epithelium
Fig. 1 Cells with overexpression of 5-LOX (marked with red
chromogene) in tubulovillous adenomas with intraepithelial moder-
ate/high-grade focal neoplasia—positive epithelium [259×202 mm
(72×72 DPI)]
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advanced neoplastic changes, including early adenocarci-
nomas in adenomatous polyps (three out of four cancers
showed a high expression of 5-LOX).
Analyzing the expression of 5-LOX in the group of all
adenomas, we observed the highest expression of 5-LOX in
all villous adenomas, which is widely recognized as one of
the high-risk features associated with malignant transfor-
mation. Among tubulovillous and tubular adenomas, the
phenomenon of high expression of this enzyme was seen
less frequently (in 79% and 49% of cases, respectively).
Similar results regarding the expression of COX-2 were
obtained by Fujita et al., who observed a high expression of
this enzyme in tubulovillous adenoma cells compared to
tubular adenomas [20].
The relationship between 5-LOX expression and the
presence of intraepithelial neoplasia in the epithelial cells of
adenomas was also found. 5-Lipoxygenase overexpression
occurred in almost half of all cases of adenomas with a
small to medium degree of intraepithelial neoplasia, but
more often it was observed within high-grade neoplastic
changes (more than 82% of cases).
A positive correlation between the expression of 5-LOX
and the size of the adenoma has also been demonstrated. A
vast majority of researchers reported a similar correlation
between the size and intensity of COX-2 expression in the
evaluation of this enzyme [21–24].
In our study, the gender of patients who underwent
polypectomy had no effect on the expression of 5-LOX in
the tested colonic adenomas, but there was a difference in
the expression of this enzyme relating to the patient’s age:
adenomas removed from patients over 60 years of age
showed an overexpression of 5-LOX more frequently (three
fourth of cases).
We observed the highest concentration of 5-LOX in
the epithelium only. 5-Lipoxygenase overexpression was
only rarely seen simultaneously in epithelial and stromal
cells. The most rare localization of overexpressed 5-LOX
cells was mucosal stroma without epithelial expression.
In their own studies on COX-2, Bamba et al. [25]a n d
Chapple et al. [5] described the partial presence of high
expression of this enzyme in cells of epithelial origin, but
both authors stressed the advantages of cells with COX-2
overexpression inside the mucosal stroma. Hardwick et al.
[26]a n dT a n a k ae ta l .[ 27] agreed and similarly found a
strong expression of COX-2 in stromal macrophages.
Arnoletti et al. published observations regarding the
dominance of high COX-2 expression in stromal cells
and additionally, in his opinion, the epithelial localization
had a direct relationship with the moment of adenomas’
malignant transformation to cancer [18]. If such a
hypothesis is correct, it may be that 5-LOX is an even
more sensitive indicator of incidence for adenomas with
high risk of malignant transformation, but this clearly
requires further research. It is possible that we could use
some information from such studies to create concepts for
future investigations, e.g., create “easy to perform” tests
for detecting adenomas with high risk of malignant
transformation or find inflammatory enzyme polymor-
phisms to help develop chemopreventive drugs.
Conclusions
(1) 5-Lipoxygenase, marked with immunohistochemical
methods, occurred in all types of adenomas.
(2) It is possible that the occurrence of 5-LOX over-
expression in adenomas smaller than 10 mm demon-
strates a greater risk of malignant transformation, but
this requires further investigation.
(3) In colonic adenomas, high expression of 5-LOX,
marked with immunohistochemical methods, may be
an additional criterion for assessing the risk of
transformation into cancer.
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